China Approves First Golimumab Biosimilar as Bio-Thera Clinches Unprecedented US-EU-China Triple in 2026
· techtimes.com · popularity 19/100 · 0 similar stories today · Pharmaceuticals & Medical Research (Health & Life Sciences)
Read the original at techtimes.com →
Summary
China's NMPA approved golimumab biosimilar ASHULI as the first in China, completing Bio-Thera's unprecedented US-EU-China regulatory trifecta in 2026.
Found in: Tech Times. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 9.